Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin–MLL Interaction with Strong In Vivo Antitumor Activity-Reference-Cited by-同舟云学术

Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin–MLL Interaction with Strong In Vivo Antitumor Activity

Published:2020-04-27 Issue:9 Volume:63 Page:4997-5010
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Xu Shilin^ORCID,Aguilar Angelo,Huang Liyue,Xu Tianfeng,Zheng Ke^ORCID,McEachern Donna,Przybranowski Sally,Foster Caroline,Zawacki Kaitlin,Liu Zhaomin,Chinnaswamy Krishnapriya,Stuckey Jeanne,Wang Shaomeng^ORCID

Funder

National Cancer Institute

Prostate Cancer Foundation

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00547

Reference38 articles.

1. MLL translocations, histone modifications and leukaemia stem-cell development

2. Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

3. New insights to the MLL recombinome of acute leukemias

4. MLL: How complex does it get?

5. When epigenetics kills: MLL fusion proteins in leukemia

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Menin signaling and therapeutic targeting in breast cancer;Current Problems in Cancer;2024-08

2. Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia;International Journal of Molecular Sciences;2024-05-30

3. Approaching the catalytic mechanism of protein lysine methyltransferases by biochemical and simulation techniques;Critical Reviews in Biochemistry and Molecular Biology;2024-03-03

4. Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors;European Journal of Medicinal Chemistry;2024-03

5. Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation;Oncology and Therapy;2024-02-01